SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Millennium Pharmaceuticals, Inc. (MLNM)
An SI Board Since February 1997
Posts SubjectMarks Bans Symbol
3044 135 0 MLNM
Emcee:  icanpickem Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2444<i> Corresponding values for the groups receiving 2.0 mg per kilogram and microcapfun-7/6/2005
2443MLN02 >> A typo???>> No. An excerpt from the original article in tIcebrg-7/6/2005
2442<b> Patients getting the low dose were three times as likely to develop anmicrocapfun-7/5/2005
2441<b> Velcade seems to have much untapped potential. </b> My feeling microcapfun-7/4/2005
2440Millennium's New CEO Targets Profit Next Year By Randall Osborne Dunsire tIcebrg-7/2/2005
2439I do not know what is her contribution to Glivec, Femara, and Zometa. Maybe she Miljenko Zuanic-6/30/2005
2438<<1. PTK has not failed yet, although it did miss an interim endpoint in pMiljenko Zuanic-6/30/2005
2437[Bortezomib: A last resort in myeloma: modest efficacy, major risks] >>Prtuck-6/30/2005
2436Still, a record that only a very small number of oncology executives can surpasstuck-6/30/2005
2435<i> While Glivec, Femara, and Zometa are doing well, failure of the PTK anDewDiligence_on_SI-6/30/2005
2434Millennium May Seek In-Licensing Deals In Next Year 06.29.05, 2:47 PM ET CreditIcebrg-6/30/2005
2433While Glivec, Femara, and Zometa are doing well, failure of the PTK and misconduMiljenko Zuanic-6/30/2005
2432>>PR omitted where she failed lately as Novartis oncology chief?<< tuck-6/29/2005
2431I guess an-intently PR omitted where she failed lately as Novartis oncology chieMiljenko Zuanic-6/29/2005
2430As a shareholder, I hope she makes out like a bandit. Clearly she's certainIan@SI-6/29/2005
2429nice deal for new ceo. investor.millennium.comsoftware salesperson-6/29/2005
2428Millennium Announces New CEO Wednesday June 29, 7:01 am ET -- Head of Novartis Nbob zagorin-6/29/2005
2427Shift Seen Atop Millennium Pharmaceuticals By ANDREW POLLACK Published: June 29Icebrg-6/29/2005
2426CXCR3 is not targeted by compounds in the Millenium pipeline, i.e., this appearstuck-6/28/2005
2425>>CXCR3 chemokine receptor, antibodies, nucleic acids, and methods of use tuck-6/28/2005
2424[Integrilin: EARLY ACS trial design and rationale in the June 2005 issue of the tuck-6/28/2005
2423[Timing of administration of bortezomib affects outcome in GVHD] >>Blood tuck-6/24/2005
2422Humanized Antibody Offers Hope in Ulcerative Colitis [Another story on MLN02. IIcebrg-6/24/2005
2421Biotech Drug Shows Promise Against Ulcerative Colitis By Ed Edelson HealthDay ReIcebrg-6/24/2005
2420Celgene's Revlimid Will Generate $321 Million in Sales for the Multiple MyelIcebrg-6/23/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News